Results 91 to 100 of about 914,658 (345)
Learning to prescribe - pharmacists' experiences of supplementary prescribing training in England [PDF]
, 2008 Background: The introduction of non-medical prescribing for professions such as pharmacy and nursing in
recent years offers additional responsibilities and opportunities but attendant training issues.A Elston, Allen Hutchinson, Anthony Avery, Centre for the Advancement of Inter-professional Education (CAIPE), Claire Anderson, D Dawoud, D Silverman, Department of Health, Department of Health, E Bradley, Elizabeth Murphy, F Lloyd, J George, Joanne Lymn, Julie Ratcliffe, L Emmerton, Louise Guillaume, M Offredy, M Tully, P Black, P Buckley, Paul Bissell, Paul Ward, R Jones, Richard J Cooper, RJ Cooper, RJ Cooper, Royal Pharmaceutical Society of Great Britain, Royal Pharmaceutical Society of Great Britain, S Morrison-Griffiths, S Warchal +30 morecore +8 more sourcesEffective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
Molecular Oncology, EarlyView.WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet +17 morewiley +1 more sourceMonitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer
Molecular Oncology, EarlyView.Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien +35 morewiley +1 more sourceTSPO: kaleidoscopic 18-kDa amid biochemical pharmacology, control and targeting of mitochondria [PDF]
, 2016 The 18-kDa translocator protein (TSPO) localizes in the outer mitochondrial membrane (OMM) of cells and is readily up-regulated under various pathological conditions such as cancer, inflammation, mechanical lesions and neurological diseases. Able to bind Aghazadeh, Aghazadeh, Alho, Amitani, Anholt, Anholt, Anholt, Anholt, Antkiewicz-Michaluk, Arbo, Banati, Banati, Bar-Ami, Barron, Basile, Batarseh, Batarseh, Batarseh, Batarseh, Batra, Beinlich, Benavides, Bernassau, Besman, Bird, Bitran, Bose, Boujrad, Boujrad, Braestrup, Bribes, Bribes, Brunette, Cagnin, Campanella, Campioli, Casellas, Chauveau, Chen, Chen, Cho, Clark, Colasanti, Corcia, Costa, Costa, Costa, Cuhlmann, Daugherty, De Souza, Decaudin, Decker, Delavoie, Delerive, Doperalski, Enders, Epstein, Fafalios, Fan, Fan, Fan, Fur, Fur, Galiegue, Gastaldello, Gatliff, Gatliff, Gavish, Gavish, Gazouli, Gehlert, Gerhard, Gervois, Giatti, Giatzakis, Giatzakis, Golani, Gonzalez-Polo, Guillon, Gulyas, Guo, Guo, Gut, Hardwick, Hardwick, Hauet, Hauet, Jamin, Jaremko, Jaremko, Jemma Gatliff, Joo, Joseph-Liauzun, Karlstetter, Kita, Kondo, Konigsrainer, Korkhov, Kreisl, Kruczek, Kumar, Lacapere, Lacapere, Lavisse, Li, Li, Li, Li, Li, Li, Libby, Liu, Liu, Maia, Maury, Mazurika, McEnery, Miao, Michelangelo Campanella, Midzak, Midzak, Miettinen, Miller, Mills, Mizrahi, Morohaku, Murail, Nagler, Obame, Oberto, Olson, Ostuni, Ouchi, Owen, Owen, Owen, Papadopoulos, Papadopoulos, Papadopoulos, Papadopoulos, Papadopoulos, Papadopoulos, Papadopoulos, Paradis, Pastorino, Pelechano, Petrescu, Poynter, Raghavan, Rey, Romeo, Rone, Rosenberg, Rosenberg, Rosenberg, Rupprecht, Rupprecht, Scarf, Schaller, Selvaraj, Shoukrun, Sileikyte, Soustiel, Sutter, Tang, Taylor, Teboul, Thompson, Trincavelli, Tu, Tu, Tu, Vanhee, Varrone, Vega, Verma, Wang, Wang, Wei, Whalin, Xiao, Yang, Yang, Yasuno, Yeliseev, Yoder, Zhang, Zhang, Zhao, Zhou +189 morecore +1 more sourceDeveloping evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking +43 morewiley +1 more sourcePharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease [PDF]
, 2013 The aim of the study was to characterize pharmacokinetics of tiotropium solution 5 µg compared to powder 18 µg and assess dose-dependency of tiotropium solution pharmacodynamics in comparison to placebo.Cornelissen, PJG, Derom, Eric, Disse, B, Hohlfeld, JM, Peterkin, V, Sharma, A, Towse, L, van Noord, JA +7 morecore +1 more sourcePARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer
Molecular Oncology, EarlyView.Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi +13 morewiley +1 more source
